TUCSON, Ariz.--(BUSINESS WIRE)--March 28, 2006--AmpliMed(R) today announced that it has begun enrollment of patients in the Phase Ib component of a Phase Ib-II clinical trial to evaluate its lead candidate, Amplimexon(R) (imexon inj.), as a stand-alone therapy in patients with multiple myeloma whose disease has begun to progress following at least two prior therapeutic campaigns, either conventional or experimental. The study is open at two centers in the United States. Information about the study can be obtained by calling AmpliMed at 520-382-0230.
